Related references
Note: Only part of the references are listed.Tu1236 Comparison of Techniques for Monitoring Infliximab Bioavailability and Immunogenicity in Crohn's Disease
Casper Steenholdt et al.
GASTROENTEROLOGY (2015)
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
Casper Steenholdt et al.
INFLAMMATORY BOWEL DISEASES (2012)
Acute and delayed hypersensitivity reactions to infliximab and adalimumab in a patient with Crohn's disease
Casper Steenholdt et al.
JOURNAL OF CROHNS & COLITIS (2012)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Casper Steenholdt et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2011)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
Klaus Bendtzen et al.
ARTHRITIS AND RHEUMATISM (2006)